Ignite Creation Date:
2025-12-24 @ 2:03 PM
Ignite Modification Date:
2026-01-20 @ 9:09 AM
Study NCT ID:
NCT04526795
Status:
TERMINATED
Last Update Posted:
2024-12-12
First Post:
2020-08-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Recurrent Acute Biphenotypic Leukemia | View |
| None | Recurrent Acute Lymphoblastic Leukemia | View |
| None | Recurrent Acute Myeloid Leukemia | View |
| None | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Recurrent T-Cell Prolymphocytic Leukemia | View |
| None | Refractory Acute Biphenotypic Leukemia | View |
| None | Refractory Acute Lymphoblastic Leukemia | View |
| None | Refractory Acute Myeloid Leukemia | View |
| None | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | View |
| None | Refractory T-Cell Prolymphocytic Leukemia | View |
Keywords: